YS VS ENZ Stock Comparison
Performance
YS10/100
10/100
YS returned -94.73% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
ENZ10/100
10/100
ENZ returned -44.04% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Volatility
YS23/100
23/100
YS has had a lower than average amount of volatility over the last 12 months giving it a score of 22 of 100.
ENZ40/100
40/100
ENZ has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Analyst Price Targets
YS
"Analyst Price Targets" not found for YS
ENZ75/100
75/100
1 analysts offer 12-month price targets for ENZ. Together, they have an average target of 0, the most optimistic target put ENZ at 0 within 12-months and the most pessimistic has ENZ at 0.
Technicals
YS
"Technicals" not found for YS
ENZ10/100
10/100
ENZ receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Profit
YS
"Profit" not found for YS
ENZ35/100
35/100
Out of the last 20 quarters, ENZ has had 6 profitable quarters and has increased their profits year over year on 5 of them.
All score calculations are broken down here to help you make more informed investing decisions
YS Biopharma Co., Ltd. Ordinary Shares Summary
Nasdaq / YS
Healthcare
Biotechnology
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
Enzo Biochem, Inc. Summary
New York Stock Exchange / ENZ
Healthcare
Medical - Diagnostics & Research
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare YS to other companies in the same or a similar industry.